Lisa Carey and Otto Metzger, discuss about the phase 3 PATINA trial
SABCS shared a post on X:
“Now on SABCS Snippets:
Lisa Carey and Otto Metzger, discuss the phase 3 PATINA trial, which showed that patients with HR+, HER2+ metastatic breast cancer had improved PFS when palbociclib was added to endocrine and anti-HER2 therapy.”
The conversation features Lisa Anne Carey, a breast medical oncologist from the University of North Carolina, and Otto Metzger, a medical oncologist at the Dana-Farber Cancer Institute in Boston, discussing the results of the PATINA study (AFT38).
The study evaluates the addition of the CDK4-6 inhibitor palbociclib to treatment for HER2-positive and hormone receptor-positive metastatic breast cancer. The trial demonstrated significant improvement in progression-free survival (PFS), with palbociclib showing a median PFS of 44.3 months compared to 29.1 months in the control group, indicating a 26% reduction in the risk of progression.
The trial also sparked a discussion on the induction chemotherapy phase and whether it is necessary for all patients, suggesting that some could potentially bypass chemotherapy and go straight to combination therapy with palbociclib. Regarding toxicity, the side effects were consistent with expectations, though there was a slightly higher incidence of diarrhea, potentially linked to prior chemotherapy. Overall, Lisa Anne Carey and Otto Metzger highlighted the promising results of the PATINA study and its implications for the future treatment of HER2-positive, hormone receptor-positive metastatic breast cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023